Upcoming Events

The GSAS Harvard Biotechnology Club 20th anniversary symposium will celebrate 20 years of student-driven connections between academia and industry. This meeting will highlight seminal achievements in biotech innovation and commercialization that have occurred since the inception of the club in 1999, especially those which have made a measurable impact on patients’ lives. A theme of fostered collaboration between industry and academia will be emphasized, with panels covering the work of entrepreneurial academic investigators and the bond of information transfer between academia and industry. Keynote speakers will provide outlooks on the unique roles of academia and industry in the ecosystem of biotechnology, and will feature Dean George Daley of Harvard Medical School, RA Capital Founder and Managing Director Peter Kolchinsky, and Vertex EVP & CSO David Altshuler. The GSAS Harvard Biotechnology Club is excited to host this meeting as one of its premier initiatives for students seeking futures in biotechnology.

Register now

Registration is underway for the 2019 Compassion in Action Healthcare Conference taking place in Boston September 8-10, 2019 at the Westin Boston Waterfront. This unique conference brings together clinicians, health system leaders, and others who are committed to making compassion a priority in their organizations and communities.

Through interactive experiential sessions with experts from diverse care settings and communities, this conference will focus on fostering compassionate leaders across all professions and roles within healthcare. Participants will leave the conference having gained inspiration, knowledge/skills, and partners to improve care quality and outcomes, patient experience, and workforce well-being through compassion and collaboration.

Register now

Biotech Week Boston is a festival of over 12 leading events and an expansive exhibit floor spanning the drug development value chain, giving you access to the most inventive scientific minds and business leaders in Boston and around the world.

Register now

The convergence between digital health and the life sciences is creating new opportunities to transform patient care as well as drug discovery and development. From wearables to machine learning, digital technologies are easing data collection from patients, increasing medical adherence, reshaping clinical trials, and offering new insights into real-world applications of therapies. Embedding digital health tools into the life sciences will also allow new therapies to better work within the growing value-based healthcare system that relies on data and measurable outcomes.

Join MassBio for their inaugural Digital Health Impact 2019 event, part of Biotech Week Boston, as they examine the current state of digital health as it relates to the life sciences, the challenges facing its growth, and opportunities for collaboration. Through keynotes, panel discussions, and case studies, they’ll explore new strategies for life sciences and digital health innovators to converge and ultimately deliver better outcomes for patients.

Register now

Medical device companies are in acquisition mode! Don’t miss lunch and a review of acquisition do’s and don’ts with the Medi-Vantage medtech advisory team. Medi-Vantage performs due diligence for a number of medical device companies to learn if (and how) the acquisition truly meets all the claims the start-up makes and to assess the true market potential. When helping with fundraising, we help to hone pitch decks and validate assumptions. Medi-Vantage is an advisory firm supporting global healthcare technology innovators on product, market and business strategy with the goal of optimizing the value of their innovations. Since 2007, Medi-Vantage has worked with >250 companies, helping them through key product decisions, fundraising and strategic transactions like M&A. Medi-Vantage’s founder and CEO, Maria Shepherd, will present insights from their experience with early stage companies and answer questions.

Register now

BioPharm America™ is a unique partnering event that forms the nexus of discovery and realization. Now in its twelfth year, BioPharm America creates a robust exchange among hundreds of executives from venture capital firms, major pharmaceutical companies, academic institutions, and biotechnology companies of every size and stage, from mature to startup. The event brings dealmakers from the life science ecosystem together to engage and de-risk the enormous task of drug development. A primary focus of BioPharm America™ is the one-to-one meetings driven by partneringONE®, the industry’s most robust software platform. Delegates can request and schedule meetings tailored to their strategic business goals to create a dynamic personalized agenda that includes regular alerts for further meeting opportunities.

The impetus behind this intensive business development activity is a two-day conference program that features thought leaders and executives from across the life science industry. To help bring attention to early stage projects and small entrepreneurial companies, BioPharm America features special tracks specifically designed for startups and young companies to get on the radar of the global life science community and to make the connections that matter. Leading pharmaceutical companies attend BioPharm America in search of innovation. Engaging panel discussions cover topics of interest to dealmakers including licensing, investment, and business development. Held in Boston each September, the event attracts 800+ delegates from over 500 companies who participate in 2,300+ scheduled one-to-one meetings. In addition, BioPharm America is now part of Biotech Week Boston, providing concurrent events and highlights which attract a total of over 4,500 life science leaders, scientists and innovators.

Register now

In this Harvard Medical School webinar, Dr. Nancy Keating will discuss how OCM focuses on 6-month episodes of care for fee-for-service Medicare beneficiaries with cancer, which are triggered by the administration of anti-cancer therapy. As a member of the OCM Evaluation Team, she will also review some findings of the early impact of the OCM, an APM focused on specialty care, on total costs of care, service utilization and quality and share plans for upcoming analyses. This webinar will help health care business leaders understand opportunities and challenges of using APMs to improve the value of oncology care delivery.

Register now